TAP Pharmaceutical Products has agreed to pay another $150 million to resolve civil suits about the marketing and pricing of its drug Lupron, pushing the company's total payouts for the prostate cancer drug to more than $1 billion. The recent cases accused TAP of selling Lupron at steeply discounted prices, guaranteeing doctors big profits on prescriptions. The agreement resolves health insurance company allegations that they were bilked out of tens of millions of dollars worth of the drug.
December 02, 2004 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Presented by BigVoodoo
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania with their dedication to law.
Recognizing innovation in the legal technology sector for working on precedent-setting, game-changing projects and initiatives.
GlobeSt. Women of Influence Conference celebrates the women who drive the commercial real estate industry forward.
We are a nationally recognized personal injury law firm focused solely on representing victims of sexual abuse located in Los Angeles. We ...
Growth opportunity with New York insurance defense firm based in New York City which is growing its Fairfield County, Connecticut practice a...
Westchester County, NY. Attorney seeking to semi-retire seeks an attorney to takeover a law firm specializing in healthcare litigation again...
MARTIN, CLEARWATER & BELL LLP COUNSELORS AT LAW IN MEMORY OF FRANCIS PETER BENSEL
GILL & CHAMAS Congratulations to our partner and friend,DAVID H. LANDE, ESQ on his appointment to Judge in the Division of Workers Compensation.
